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Vitamin D deficiency, observed mainly in the geriatric population, is
responsible for loss of bone mass and increased risk of bone fractures.
Currently, recommended doses of cholecalciferol are advised, but
since there are few studies evaluating the factors that influence the
serum levels of 25-hydroxyvitamin D (25(OH)D) following supple-
mentation, we analyzed the relationship between the increase in serum
25(OH)D after supplementation and body fat. We studied a group of
42 homebound elderly subjects over 65 years old (31 women) in order
to assess whether there is a need for adjustment of the doses of
cholecalciferol administered to this group according to their adipose
mass. Baseline measurements of 25(OH)D, intact parathyroid hor-
mone and bone remodeling markers (osteocalcin and carboxy-termi-
nal fraction of type 1 collagen) were performed. Percent body fat was
measured by dual-energy X-ray absorptiometry. The patients were
divided into three groups according to their percent body fat index and
were treated with cholecalciferol, 7,000 IU a week, for 12 weeks. The
increases in serum levels of 25(OH)D were similar for all groups,
averaging 7.46 ng/mL (P < 0.05). It is noteworthy that this increase
only shifted these patients from the insufficiency category to hypovi-
taminosis. Peak levels of 25(OH)D were attained after only 6 weeks of
treatment. This study demonstrated that adipose tissue mass does not
influence the elevation of 25(OH)D levels following vitamin D sup-
plementation, suggesting that there is no need to adjust vitamin D dose
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Introduction
Vitamin D insufficiency has been diag-
nosed mainly in the elderly and is respon-
sible for the loss of bone mass, leading to an
increased risk of bone fractures. Low levels
of vitamin D are related to secondary hyper-
parathyroidism and elevation in the levels
of bone remodeling markers (1-4). Several
factors are considered determinants of base-
line serum levels of 25-hydroxyvitamin D
(25(OH)D). These include age, race and sea-
son of the year; other factors such as obesity,
however, have been studied only recently
(5-7).
Some specific characteristics of vitamin
92
Braz J Med Biol Res 39(1) 2006
M.H.S. Canto-Costa et al.
D physiology have been associated with
obese people. Serum parathormone (PTH)
and 1,25-dihydroxyvitamin D (1,25(OH)2D)
levels are elevated in obese men and women
but serum 25(OH)D levels are lower when
compared to non-obese individuals (6,7).
Elevation of urinary cyclic AMP levels and
a decrease of serum calcium levels have also
been described in these patients when com-
pared to non-obese people matched for age
(8). Although the explanation for the in-
crease in the risk of vitamin D deficiency in
the obese individuals is unknown, it has
been postulated that this population, due to
lower mobility, is less exposed to sun radia-
tion which is crucial for skin synthesis of
vitamin D (9). It is also assumed that an
increase in production of the active form of
vitamin D (1,25(OH)2D) plays a role in the
negative feedback over liver hydroxylation,
limiting the synthesis of 25(OH)D (6).
In the 1970’s, some studies were pub-
lished reporting a correlation between vita-
min D and fat tissue: Mawer et al. (10)
demonstrated that parenterally administered
radiolabeled vitamin D was found in high
concentrations in adipose tissue. Liel et al.
(7), when evaluating people with morbid
obesity, suggested that the decrease of se-
rum 25(OH)D in this population could be
secondary to a change in the distribution of
vitamin D associated with increased vitamin
D storage in adipose tissue. Worstman et al.
(11) compared the elevation of serum levels
of 25(OH)D in obese and non-obese indi-
viduals after exposure to UVB radiation and
after orally administered ergocalciferol, con-
firming the reduction in vitamin D bioavail-
ability in obese individuals. On the basis of
this evidence, obese people would be ex-
pected to need higher doses of supplemen-
tary vitamin D than thin people.
In the last few years, with the advances in
the study of osteoporosis in elderly people, a
strong correlation between low bone mass
and vitamin D insufficiency was found in
the elderly (12). These observations changed
the way how one determines the ideal levels
of vitamin D. In this regard, deficiency was
formerly accepted as levels associated with
osteomalacia. Currently, the trend toward
elevation of PTH levels is accepted to char-
acterize hypovitaminosis D, being related to
elevation of risk of bone fractures (13,14). It
is important to know which factors influence
the serum levels of vitamin D and which
factors modify these levels after vitamin D
supplementation, so that inadequate treat-
ment can be avoided. Adiposity seems to
play a role in the decrease of vitamin D
levels; however, it remains unclear whether
it interferes with elevation of these levels
after vitamin D replacement.
We studied 42 geriatric patients living in
a nursing home in São Paulo, SP, Brazil.
They received oral vitamin D (cholecalcif-
erol) on a weekly basis for 3 months. Serum
vitamin D levels and their correlation with
adipose tissue parameters were evaluated.
Subjects and Methods
All subjects were over 65 years old and
had been living in a nursing home in São
Paulo, SP, Brazil, for at least 6 months. After
initial selection, we excluded patients with
renal problems (serum creatinine >1.4 mg/
dL), elevation of liver enzymes (ALT and
AST), primary hyperparathyroidism, other
causes of hypercalcemia, hypercalciuria, end-
stage diseases, Paget disease, past history of
nephrolithiasis, bedridden patients, and pa-
tients using medications known to interfere
with bone metabolism such as corticoste-
roids, bisphosphonates, anticonvulsants,
lithium, thiazide diuretics, sodium fluoride,
vitamin D and/or calcium. On this basis, of
55 patients initially selected, 31 women and
11 men participated in and concluded the
study. The study was approved by the Ethics
Committee of the Federal University of São
Paulo and all subjects signed an informed
consent form. All patients were able to walk
and carry out their daily living activities and
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were capable of understanding the objec-
tives of the study. Daily calcium intake,
based on reported weekly food intake, aver-
aged less than 500 mg a day.
Total calcium (reference values (RV):
8.4-10.2 mg/dL), ionic calcium (RV: 1.15
and 1.40 mmol/L), magnesium (RV: 1.9-2.5
mg/dL), albumin (RV: 3.5-5.0 g/dL), and
creatinine (RV: 0.8-1.2 mg/dL) were meas-
ured and analyzed using standard protocol
of the laboratory (UNIFESP). An electro-
chemiluminescence immunoassay (Elecsys
analyzer, Roche, Mannheim, Germany) was
used to measure PTH (RV: 15-65 pg/mL),
carboxyl-terminal fraction of type 1 collagen
(CTX-s; RV: 0.010-5.94 ng/mL) and osteo-
calcin (OC; RV: 11-43 ng/mL). Levels of
25(OH)D were measured by HPLC using a
Chromsystem kit (Munchen, Germany), rang-
ing from 10 to 60 ng/mL (mean total coeffi-
cients of variation were 10%). Blood samples
reserved for the measurement of PTH were
stored in cooled tubes and conserved in ice.
All samples were centrifuged for about 1 h
after collection. Serum samples were distrib-
uted into vials and kept in a freezer until the
measurements, except for ionic calcium deter-
mination, which was carried out immediately.
Vitamin D (cholecalciferol) drops (Mag-
ister Handling Pharmacy Ltd., São Paulo,
SP, Brazil), 1,000 IU/drop, were adminis-
tered. The content of vitamin D found in this
medication was analyzed by Tishcon Corp.
(Westbury, NY, USA) revealing 1,100 IU/
drop. The medication was handled all at
once and conserved at a temperature of 8ºC
protected from light.
Each participant was submitted to a total
body scan using dual-energy X-ray absorp-
tiometry with a radiation densitometer
(HOLOGIC, model 4500 A, Waltham, MA,
USA). The coefficient of variation for total
body fat measurements was 1.26%.
Study design
This was a prospective 3-month study.
The untreated group was composed of 11
patients chosen for their lower but still nor-
mal levels of PTH because they would not
receive any sort of treatment, and our main
objective regarding this group was to con-
firm the stability of 25(OH)D levels during
the study. The remaining patients received
cholecalciferol, 7,000 IU a week for 12
weeks, personally provided by one of the
authors who counted drops once a week for
all patients. The patients were divided into
three groups of similar size according to
their total body fat (TBF) percentages: TBF
< 25% (N = 10), 25% < TBF < 38% (N = 11)
and TBF > 38% (N = 10). Biochemical tests,
25(OH)D, PTH, OC, and CTX-s were first
measured before the beginning of cholecal-
ciferol supplementation. Two further blood
samples were obtained within 6 and 12 weeks
of the beginning of the study. PTH, 25(OH)D
and ionic calcium were measured during the
sixth week. In addition to these tests, OC and
CTX-s were also measured at the end of the
study.
Statistical analysis
To quantify the differences between the
treated and untreated groups regarding the
variables measured as a function of time, we
used analysis of variance (ANOVA) with
repeated measurements. In this model, two
factors were taken into account: groups
(treated and untreated) and time (0, 6, and 12
weeks). The correlations between variables
were determined by Pearson’s linear corre-
lation coefficient. To evaluate the influence
of baseline values of 25(OH)D on its eleva-
tion after treatment, we divided the treated
patients into two groups: 25(OH)D lower
than 20 ng/mL (insufficiency) and 25(OH)D
higher than 20 ng/mL. The two groups were
then compared using the Student t-test. Sta-
tistical analysis was carried out using the
SPSS and proc MIXED software of SAS. A
P value lower than 0.05 was taken to indicate
a statistically significant difference.
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Results
The mean age of the patients studied was
77.5 years, ranging from 65 to 92 years old.
Patients ranged from lean to grade 2 obesity.
Body mass index (BMI) ranged from 15.62
to 36.68 kg/m2 (data not shown). The un-
treated group had significantly lower (P <
0.05) PTH levels than the treated groups
because they were selected for low levels of
PTH. There was also no difference among
groups regarding bone remodeling markers
(CTX-s and OC; Table 1).
Seventeen 17/42 (40.4%) patients had
insufficient levels of vitamin D, <20 ng/mL,
prior to the beginning of cholecalciferol sup-
plementation. No patient had levels compat-
ible with deficiency, <5 ng/mL. Only one
female 1/42 (2.38%) patient presented suffi-
cient levels, >40 ng/mL, on the occasion of
the first blood collection. At the end of the
study, 4 treated patients (12.9%) still had
vitamin D levels lower than 20 ng/mL and
only 2/42 (4.7%) patients had levels of 40
ng/mL or more (Figure 1). No patient had
any kind of adverse effects or showed intol-
erance to the medication. Hypercalcemia was
not observed in any patient during this study,
but most patients reached only the hypovita-
Table 1. Basal and 12-week levels of 25(OH)D, PTH, CTX-s, OC, and total calcium in the untreated group and in the groups treated with
cholecalciferol, 7000 IU/week, and divided into groups according to body fat percentage.
Untreated group TBF < 25% 25% < TBF < 38% TBF > 38%
Median age = 76 years Median age = 76 years Median age = 73 years Median age = 77 years
Male/female = 4/7 (N = 11) Male/female = 3/7 (N = 10) Male/female = 4/7  (N = 11) Male/female = 4/6 (N = 10)
    Basal  12 weeks Basal   12 weeks    Basal   12 weeks    Basal   12 weeks
25(OH)D (ng/mL) 24.5 ± 7.1 21.8 ± 9.2 18.8 ± 6.4 25.0 ± 6.0a 22.4 ± 10.7 30.5 ± 6.5a 24.2 ± 7.4 32.3 ± 7.0a
PTH (pg/mL) 29.6 ± 8.2b 36 ± 12.2 58.6 ± 17.5 57.2 ± 30.5 51.2 ± 28.1 52.8 ± 25.4 53.6 ± 28.6 50.1 ± 25.1
CTX-s (ng/mL) 0.53 ± 0.2 0.51 ± 0.12 0.54 ± 0.23 0.73 ± 0.31 0.79 ± 0.57 0.67 ± 0.48 0.65 ± 0.34 0.52 ± 0.33
OC (ng/mL) 25.6 ± 8.6 27.1 ± 8.1 26.2 ± 8.1 35.1 ± 18.1 40.2 ± 22.8 40.9 ± 20.8 34.5 ± 14.2 33.9 ± 16.6
Ca T (mg/dL) 8.8 ± 0.3 8.9 ± 0.2 8.8 ± 0.3 8.8 ± 0.2 8.8 ± 0.4 8.8 ± 0.3 8.84 ± 0.4 8.8 ± 0.3
Data are reported as mean ± SD. The untreated group was selected for low PTH levels. TBF = total body fat; 25(OH)D = 25-hydroxyvitamin D; PTH
= parathormone; CTX-s = carboxyl-terminal fraction of type 1 collagen; OC = osteocalcin; Ca T = total calcium.
aP < 0.05 for 12-week values compared to basal values; bP < 0.05 for basal PTH levels of the untreated group compared to the other groups
(ANOVA).
minosis levels (20-40 ng/mL) (15).
The non-treated group had a 2.7 ng/mL
non-significant decrease of the serum levels
of 25(OH)D at the end of 12 weeks. Serum
25(OH)D levels similarly and significantly
increased in the groups that received vitamin
D supplementation. The mean elevation was
of 6.2 ng/mL in the group with body fat
percentage lower than 25% and of 8.1 ng/
mL in the groups with body fat percentage
between 25 and 38% and higher than 38%;
hence, no influence of body fat percentage
on the increase of serum 25(OH)D was found
(Table 1). After 6 weeks of treatment, serum
levels of 25(OH)D reached a plateau, with
the 12-week levels almost identical to those
observed at 6 weeks. The elevation of
25(OH)D levels was not associated with
changes in CTX-s or OC (Table 1). We
observed no gender differences regarding
basal, 6- or 12-week serum 25(OH)D levels.
PTH levels did not vary significantly in ei-
ther group during the 12-week period of
study. Nine patients distributed among all
the TBF groups (21.42%) had PTH levels
higher than reference values and normal cal-
cium levels, indicative of a diagnosis of
secondary hyperparathyroidism. These pa-
tients also had the highest values of bone
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remodeling markers (OC and CTX-s; P <
0.05), but not the lowest 25(OH)D levels,
and at the end of 12 weeks their mean PTH
levels decreased from 86.46 to 70.81 pg/mL
(P < 0.05) but with no significant decrease in
the levels of bone remodeling markers (data
not shown).
Mean elevation in 25(OH)D levels among
the patients who received cholecalciferol
and presented baseline levels lower than 20
ng/mL was 10.15 versus 5.18 ng/mL for the
patients presenting baseline levels higher
than 20 ng/mL (P < 0.05; Figure 2).
Discussion
This was a short-term study designed to
evaluate the need to tailor vitamin D doses to
body fat, BMI and weight for patients who
are over 65 years old. Some studies demon-
strated that obese people have lower serum
levels of vitamin D when compared to non-
obese people (6-11), but few data are avail-
able in the literature regarding the influence
of weight or percent body fat on the eleva-
tion of serum 25(OH)D levels after vitamin
D supplementation (11). With this in mind,
we decided to study a population of institu-
tionalized geriatric patients without extreme
weights.
Baseline levels of vitamin D are mainly
influenced by the seasons of the year, race,
age, and vitamin intake (16-18). The role of
obesity has been recently evaluated. Comp-
ston et al. (9) conducted the first studies
comparing the baseline levels of vitamin D
between obese and non-obese people and
observed that the levels were significantly
lower in obese individuals. In their study,
the obese population consisted of patients
with morbid obesity.
Parikh et al. (19) studied adults of both
genders of various races and observed that
the obese group (N = 154; mean BMI 37.4 ±
6 kg/m2) displayed mean levels of plasma
25(OH)D of 23.5 ± 12.2 ng/mL, significant-
ly lower than those observed in the non-
obese group (N = 148, mean levels of
25(OH)D of 31 ± 14.4 ng/mL). Arunabh et
al. (20) evaluated a group of 410 healthy
women aged 20 to 80 years with BMI rang-
ing from 17 to 30 kg/m2 and, after adjust-
ments for race, age, season of the year, and
vitamin intake, found a discrete but signifi-
cant correlation (r = -0.13, P = 0.013, mul-
tiple regression model) between serum lev-
els of 25(OH)D and body fat percentage.
However, this significance was detected only
when distributing the study group into
quartiles and by comparing the highest body
fat percentage quartile (fat >42%) with the
lowest one (fat <31%), with the average
serum levels of 25(OH)D obtained being
17.68 and 22.64 ng/mL, respectively.
Scragg et al. (21) evaluated a group of
390 New Zealand inhabitants consisting of
natives and of people of European descent
and, similar to our findings, they did not
detect any relation between serum levels of
25(OH)D and BMI. In our study there were
no differences in baseline serum levels of
Figure 1. Effect of cholecalcif-
erol on plasma 25(OH)D (ng/
mL) at the beginning of the study
and after 12 weeks. The sub-
jects received 7000 IU/week of
cholecalciferol. 25(OH)D = 25-
hydroxyvitamin D.
Figure 2. Variation of 25(OH)D
levels among the groups of pa-
tients that received cholecalcif-
erol for 12 weeks according to
their initial levels of plasma
25(OH)D: lower than 20 ng/ml
(N = 15, left) and higher than 20
ng/mL (N = 16, right). Basal val-
ues are given in the open col-
umns and final values are given
in the filled columns. 25(OH)D =
25-hydroxyvitamin D. *P < 0.05
for the comparisons shown (Stu-
dent t-test).
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25(OH)D among the groups when they were
divided according to body fat percentage
(<25%, 25-38%, and >38%). It is important
to consider that we studied a geriatric popu-
lation and none of our patients had extreme
weight values.
Vitamin D supplementation is recom-
mended to aged patients presenting loss of
bone mass, regardless of its severity (22).
Along with calcium intake, it represents the
basic treatment of osteoporosis. Chapuy et
al. (23) were able to demonstrate a reduction
in the risk of femoral neck fractures in aged
patients receiving only calcium and vitamin
D. Still, one question remains unanswered:
what is the ideal dose of vitamin D to be
recommended so that sufficient serum levels
of 25(OH)D can be reached? In the last few
years, the recommended dose for people
aged over 70 years has varied from 600 to
2,000 IU of cholecalciferol a day, well be-
low the toxic doses (24). Lips et al. (25), in a
multicenter study, observed that supplemen-
tation of 400 to 600 IU cholecalciferol a day
promoted a mean elevation of vitamin D
levels of 8.6 ng/mL. Barger-Lux et al. (17)
administered cholecalciferol, 1,000 IU a day,
for 8 weeks to a group of healthy young men
(N = 116), and at the end of this period
verified a mean elevation of 11.44 ng/mL in
serum levels of 25(OH)D. Our geriatric pa-
tients received 7,000 IU of cholecalciferol a
week for 12 weeks and presented a mean
increase in 25(OH)D levels of 7.60 ± 6.8 ng/
mL, quite evident after only 6 weeks of
supplementation. These levels remained
stable between 6 and 12 weeks, allowing us
to assume that the elevation peak was reached
within 6 weeks or less of supplementation.
This dose was only enough to shift most of
our patients from insufficiency to hypovita-
minosis.
More recently, there have been some
issues regarding which factors influence the
elevation of serum levels of 25(OH)D after
vitamin D supplementation. As the chemical
process of hepatic hydroxylation is satu-
rable, it is expected that the individuals show-
ing lower starting levels of 25(OH)D will
present a greater increase in serum levels of
vitamin D (17). In our study, patients pre-
senting basal levels of 25(OH)D lower than
20 ng/mL (mean levels of 13.31 ± 3.1 ng/
mL), compatible with vitamin D insuffi-
ciency, reached mean values of 22.7 ± 4.9
ng/mL by the end of the study. This differ-
ence was significantly higher than that ob-
served in patients with basal levels of
25(OH)D higher than 20 ng/mL, whose vita-
min D levels varied from 28.22 ± 5.0 ng/mL
at the beginning of the study to 33.47 ± 6.1
ng/mL after 12 weeks of vitamin D supple-
mentation. Francis et al. (26), studying a
group of 65- to 80-year-old individuals in
England receiving 1,000 IU of cholecalcif-
erol a day, observed a baseline serum level
of 25(OH)D of 14.4 ng/mL that rose to 24.4
ng/mL at the end of 6 months of treatment.
In turn, Sorva et al. (27), after providing
elderly people with cholecalciferol, 1,000
IU a day, reported an elevation of 25(OH)D
from 4.8 to 22.8 ng/mL at the end of 9
months.
In addition to the starting level of
25(OH)D, weight or body fat percentage has
been implicated by some investigators as a
determinant of the variation in vitamin D
levels after supplementation. Barger-Lux et
al. (17) reported that, after giving cholecal-
ciferol, 800 IU a day, for 8 weeks to a group
of young adults, there was an elevation of
about 5.6 ng/mL for those weighing around
55 kg, and of 3.6 ng/mL for those weighing
around 85 kg. We divided the participants in
our study into three groups: those with body
fat percentage lower than 25%, between 25
and 38%, and higher than 38%, and ob-
served a mean rise in serum levels of
25(OH)D of 6.2 ± 6.9 ng/mL for the first
group and of 8.1 ± 8.5 and 8.1 ± 5.3 ng/mL,
respectively, for the other two groups, mean-
ing that no relationship between elevation of
serum levels of 25(OH)D and fat percentage
was observed.
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The same studies that observed a nega-
tive correlation between vitamin D and adi-
pose tissue also demonstrated higher levels
of PTH in obese individuals (6-11). In our
study, we did not observe any correlation
between 25(OH)D and body fat tissue or
between PTH and adiposity.
We did not find any correlation between
elevation of serum levels of 25(OH)D and
body fat percentage, weight or BMI in this
group of institutionalized patients. The
groups with different body fat percentages
had very similar elevations in the levels of
25(OH)D after vitamin D supplementation.
When these patients were provided with
cholecalciferol, they at most progressed to
hypovitaminosis, meaning that cholecalcif-
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